Compare AbCellera Biologics Inc (ABCL) vs American Homes 4 Rent Class A (AMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs American Homes 4 Rent Class A — how do they compare? AbCellera Biologics Inc trades at $10 (market cap $2.99B), while American Homes 4 Rent Class A trades at $33.82 (market cap $12.28B). The key difference: American Homes 4 Rent Class A is far larger — about 4.1× AbCellera Biologics Inc's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AMH | |
|---|---|---|
Market Cap | $2.99B | $12.28B |
Sector | Health | Real Estate |
52-Week High | $9.76 | $35.82 |
52-Week Low | $2.78 | $27.38 |
Enterprise Value | $2.58B | $17.35B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
AMH trades at $33.73, down 1.17% today, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 FFO of $0.49 per share, beating estimates, and raised full-year guidance. Revenue growth is steady, with net income margin improving to 25.53% in 2026. Analysts maintain a Moderate Buy consensus with a $36.45 price target, indicating potential upside from current levels.
Outlook is positive due to consistent earnings beats and robust rental demand, but risks include high debt levels and regulatory changes affecting institutional home buying. The stock offers value with a P/E of 27.09 and dividend yield support, though investors should monitor interest rate sensitivity and housing market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →
